Germany's Bayer AG says it has submitted an application seeking authorization to sell its new anti-clotting drug Rivaroxaban within the European Union, AP reported. The company said Wednesday it is seeking approval from the European Medicines Agency to sell the blood thinner to prevent strokes in people with a common heart rhythm problem and treat deep vein thrombosis. Rivaroxaban is being developed by Bayer HealthCare and U.S. pharmaceutical company Johnson & Johnson, based in New Brunswick, New Jersey. -- SPA